TODD BENDER: Open Payments
NPI 1013360767 · LILBURN, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,092 in 117 payments from 25 companies in 2025. Trend: 2023 $2,097 · 2024 $2,407 · 2025 $2,092
Food & beverage: $2,092
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 35 | $584 |
| Sumitomo Pharma America, Inc. | 20 | $242 |
| Amgen Inc. | 15 | $196 |
| GlaxoSmithKline, LLC. | 7 | $183 |
| Novo Nordisk Inc | 5 | $148 |
| PFIZER INC. | 6 | $123 |
| Otsuka America Pharmaceutical, Inc. | 4 | $89 |
| AstraZeneca Pharmaceuticals LP | 3 | $60 |
| Lundbeck LLC | 2 | $51 |
| Astellas Pharma US Inc | 2 | $45 |
Products named: QULIPTA, GEMTESA, REXULTI, Wegovy, OTEZLA, AREXVY, VRAYLAR, UBRELVY.
Industry payments across GA — which companies pay providers there.
